Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.38 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15933034 | 0.91 | ALK (0.84) | ALKACVR1TGFBR1HTR7HTR1A | |
| Hydrochloric Acid SCHEMBL17310251 | 0.90 | ALK (0.83) | ALKACVR1TGFBR1HTR7HTR1A | |
| SCHEMBL15933044 | 0.89 | ALK (0.75) | ALKACVR1TGFBR1HTR7 | |
| SCHEMBL15933043 | 0.87 | ALK (1.00) | ALKACVR1TGFBR1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL17310211 | 0.86 | ALK (0.98) | ALKACVR1TGFBR1CHRNB2CHRNA4 | |
| SCHEMBL15933042 | 0.85 | ALK (1.00) | ALKACVR1TGFBR1CHRNB2CHRNA4 | |
| SCHEMBL15933040 | 0.85 | ALK (0.88) | ALKACVR1TGFBR1CHRNB2CHRNA4 | |
| SCHEMBL17404654 | 0.81 | ALK (0.69) | ALKNR3C2SLC2A1SLC2A3 | |
| SCHEMBL17404673 | 0.80 | ALK (0.60) | ALKKHK | |
| SCHEMBL15932988 | 0.79 | ALK (0.62) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | ALK 853/4885ADRB1 1059/4885ACVR1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.